Longevity AI

Cover Block

Open sources

Name	Longevity AI
Tagline	Healthcare software and clinical co-pilot for evidence-based longevity care at scale.
Headquarters	New York, United States
Founded	2021
Stage	Generating Revenue [Longevity AI]
Business Model	SaaS
Industry	Healthtech
Technology	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Guy Leitersdorf (Founder & CEO) [Longevity AI]
Funding Label	$5M (total disclosed)

Links

Open sources

• Website: https://www.longevity-ai.com/
• LinkedIn: https://linkedin.com/in/guy-leitersdorf-21b10891

What an Investor Needs First

Open sources

Longevity AI is building a software platform to operationalize evidence-based longevity medicine, a bet that the clinical management of aging will become a scalable, data-driven service line for clinics. The company's primary asset is a proprietary longitudinal dataset, sourced from research partnerships with large health networks, which grounds its AI co-pilot and differentiates it from tools built on public models alone [Longevity AI, 2026]. Founded in 2021 and operating from New York and Tel Aviv, the company has raised a total of $5 million across two undisclosed rounds, positioning it in the early revenue stage with a SaaS model targeting medical practices [Crunchbase] [Tracxn, 2026].

The core product combines a unified patient data dashboard with "Florence," a clinical-grade LLM designed to extract insights from medical records and generate personalized care plans, aiming to reduce administrative burden and standardize proactive interventions [Longevity AI, 2026]. Initial traction is signaled by a deployed partnership with Clalit Health Services in Israel and a stated presence within the U.S. market, though specific clinic counts and revenue figures are not public [Crunchbase].

Leadership includes CEO and founder Guy Leitersdorf, supported by a team with operational roles in product, sales, and research spanning both commercial and technical domains [LinkedIn, 2026]. Over the coming 12-18 months, key milestones to monitor will be the expansion of the Clalit deployment, the signing of additional named health system partners in North America, and the translation of early clinic deployments into published renewal and expansion metrics.

Partially corroborated -- Core product claims and team composition are confirmed by the company's website and LinkedIn profiles; funding total is reported by secondary databases but round details are not public.

Taxonomy Snapshot

Axis	Classification
Business Model	SaaS
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Funding	$5M (total disclosed)

Inside the Company

Open sources The company was incorporated as Longevity AI in 2021, with its operational headquarters in New York City and a significant presence in Tel Aviv [Crunchbase]. The founding narrative centers on leveraging large-scale clinical data to build an evidence-based software layer for the emerging longevity medicine market. A key operational milestone was the establishment of a research partnership with Clalit Health Services, one of Israel's largest integrated health networks, which provided access to a longitudinal dataset spanning over 20 years for more than 5 million patient lives [Longevity AI, 2026]. This partnership, announced after the company's formation, appears to be the cornerstone of its proprietary data advantage.

The company's timeline shows two undisclosed funding events in January 2024 and May 2025 [Tracxn, 2026], culminating in a total of $5 million in disclosed capital raised. The team has grown to between 11 and 50 employees [LinkedIn, 2026], with executive hires in commercial and operational roles such as Chief Revenue Officer and Chief Operating Officer occurring post-funding. The product, including the Florence clinical co-pilot, is reported to be deployed with Clalit and live within the U.S. market [Crunchbase].

Partially corroborated -- Core dates and locations are consistent across sources, but specific founding details and early milestones rely on the company's own website.

Under the Hood

Reported and inferred

The product is a software platform for longevity clinics, built around a central AI agent named Florence. The core proposition is to give clinicians a single, continuously updated view of each patient by integrating disparate data streams, including electronic medical records, laboratory results, and continuous wearable data [Crunchbase] [3]. This unified biological risk profile is aligned on a longitudinal patient timeline, a method designed to help physicians identify aging trajectories and potential health risks earlier than traditional episodic reviews.

Florence, the clinical co-pilot, is the engine that operationalizes this data. The company describes it as a clinical-grade large language model grounded in a proprietary dataset of over 10,000 clinically validated studies and 1.6 million electronic health records spanning decades. This longitudinal dataset originates from research partnerships with two of the world's largest integrated health networks, one of which is publicly named as Clalit Health Services [24]. Florence's advertised functions include reading and extracting highlights from health report PDFs in under a minute and translating complex insights into personalized, actionable guidance for patients to build daily health habits [Crunchbase].

The platform appears to be deployed in a live, revenue-generating capacity. It is reported to be in use with Clalit Health Services and is live within the U.S. [Crunchbase]. While the exact tech stack is not detailed, active hiring for an AI Engineer role in Tel Aviv suggests a continued investment in core machine learning infrastructure (inferred from job postings) [21]. The system is designed to surface cross-domain patterns and offer structured summaries, positioning it as a clinical decision support tool rather than a diagnostic replacement.

Open sources The market for clinical longevity software is emerging from a period of scientific validation into one of commercial deployment, driven by a convergence of demographic pressure, technological enablement, and a shift toward value-based care.

Quantifying the total addressable market for this specific software wedge is challenging, as it sits at the intersection of several larger, adjacent markets. The most directly analogous sizing comes from the broader longevity and anti-aging market, which one analysis projects to reach $44.2 billion by 2030, growing at a compound annual rate of 8.5% [Grand View Research]. A more focused lens is the digital health market for chronic disease management, which exceeded $20 billion in 2023 and is forecast for continued high-single-digit growth [Precedence Research]. Longevity AI's platform, targeting concierge and longevity clinics, initially addresses a narrower serviceable obtainable market (SOM) within the high-end preventive care segment.

The demand tailwinds are multi-faceted. An aging global population is increasing the prevalence and cost of age-related chronic diseases, creating acute pressure on healthcare systems to adopt preventive models. Concurrently, the consumerization of health, fueled by wearable technology and direct-to-consumer testing, has created a cohort of patients actively seeking data-driven, personalized health optimization. This aligns with a broader industry shift from fee-for-service to value-based care, which financially rewards outcomes and prevention over volume of procedures. These drivers are substantiated in broader market analyses of digital health adoption [Rock Health].

Key adjacent and substitute markets highlight both the opportunity and the competitive context. The company's platform competes indirectly with enterprise electronic health record (EHR) vendors adding wellness modules, standalone digital therapeutics (DTx) for specific conditions, and a growing ecosystem of direct-to-consumer longevity apps and testing services. The regulatory landscape presents a dual force: while FDA clearance for software as a medical device (SaMD) can be a barrier, it also serves as a moat for clinical-grade tools. Macro forces, including healthcare labor shortages, further incentivize the adoption of AI-assisted clinical co-pilots to augment physician capacity.

Longevity & Anti-Aging Market (2030) | 44.2 | $B
Digital Chronic Disease Management (2023) | 20.1 | $B

The available sizing data, while not specific to clinical longevity software, frames the venture-scale opportunity within larger, validated healthcare IT and consumer wellness trends. The growth rates suggest a receptive and expanding economic environment for the company's category.

Partially corroborated -- Market sizing figures are from third-party analyst reports for analogous sectors, not the specific niche. Tailwind analysis is corroborated by multiple industry publications.

Competition and Substitutes

Reported and inferred Longevity AI is positioned as a clinical software layer for longevity clinics, a wedge that separates it from both pure-play biotech platforms and general-purpose electronic health record systems.

The competitive map must instead be constructed from adjacent market segments. The landscape can be segmented into three broad categories: direct clinical software rivals, adjacent health data platforms, and deep-science biotech companies.

• Clinical software and co-pilot rivals. This is the most direct competitive arena, though specific private companies are not named in the sources. The space includes other startups building AI dashboards for concierge medicine, functional medicine, and longevity clinics. These competitors typically lack the proprietary longitudinal dataset Longevity AI claims through its research partnerships. The company's edge today appears to be its access to a specific, large-scale dataset from Israeli health networks, which grounds its Florence co-pilot [Longevity AI, 2026]. This edge is durable only as long as exclusive data access is maintained and the dataset's clinical relevance for longevity prediction remains superior to alternatives.
• Adjacent health data platforms. These include large-scale population health management platforms and next-generation EHRs that are adding wellness and predictive modules. Companies like Tempus or Komodo Health operate in the oncology and broader healthcare analytics spaces, respectively. Their scale and capital are a long-term threat, but their focus is typically on specific diseases or broad population health, not the niche of proactive, evidence-based longevity care. Longevity AI's exposure here is that these well-funded incumbents could decide to build or acquire a longevity-specific module, leveraging their existing hospital distribution.
• Deep-science biotech companies. Firms like NewLimit (epigenetic reprogramming) and Fountain Life (preventive diagnostics networks) were surfaced in research as distinct entities [Perplexity Sonar Pro Brief]. They are not software competitors but represent alternative capital and attention within the longevity ecosystem. They compete for the same investor dollars and clinic partnerships. Longevity AI is most exposed if a major biotech player with deep pockets, like Fountain Life with its reported $108 million in funding, decides to vertically integrate by building or buying a software layer for its own clinic network [Perplexity Sonar Pro Brief].

The most plausible 18-month scenario hinges on distribution. A winner will likely be the company that successfully locks in partnerships with large, integrated health networks beyond its initial beachhead. If Longevity AI can replicate its Clalit Health Services partnership in another major U.S. or European network, it would solidify its data moat and create a significant barrier [Crunchbase]. Conversely, a loser would be any pure-software player that fails to move beyond early-adopter boutique clinics and cannot demonstrate improved patient outcomes or clinician efficiency at scale, leaving them vulnerable to being displaced by a platform with deeper integration or a broader product suite.

Partially corroborated -- Competitive analysis is inferred from market segments and adjacent company data; no direct competitors are named in confirmed sources.

Opportunity

Open sources The prize for Longevity AI is a foundational software layer in a clinical longevity market that could scale from niche concierge medicine to a standard component of primary care.

The headline opportunity is to become the category-defining clinical operating system for evidence-based longevity medicine. The company's early deployment with Clalit Health Services, one of the world's largest integrated health networks, provides a critical wedge [Crunchbase]. This partnership grants access to the longitudinal patient data required to train its Florence co-pilot, grounding the product in real-world clinical workflows rather than speculative wellness. If the platform can demonstrate improved patient outcomes and operational efficiency within such a large, complex system, it establishes a credible pathway to becoming the default software for any clinic seeking to add structured longevity protocols. The outcome is reachable because the company is already embedded within a major payer-provider, solving the initial data-access and distribution challenges that stall most healthcare AI startups.

Several concrete paths could accelerate this scaling. The scenarios below outline how growth might unfold from the current beachhead.

Scenario	What happens	Catalyst	Why it's plausible
Clalit as a launchpad for Israel	The initial research partnership evolves into a full commercial deployment across Clalit's hundreds of clinics, making Longevity AI the standard for preventive care in a national health system.	A published outcomes study from the research partnership demonstrating cost savings or reduced hospitalizations.	The company already has a "big data research partnership" with Clalit and access to its datasets [Crunchbase]. Israeli health tech has a history of scaling from domestic system wins to global exports.
U.S. specialty clinic land-and-expand	The platform is adopted by leading U.S. concierge longevity clinics, then expands into adjacent high-value specialties like cardiometabolic health and oncology survivorship programs.	A flagship partnership with a top-tier U.S. longevity clinic chain (e.g., a group like Fountain Life).	The company lists clinics in the U.S., Canada, Mexico, and Latin America as its customer base, indicating an existing commercial foothold in the specialty clinic market [Perplexity Sonar Pro Brief].

What compounding looks like centers on the proprietary dataset. Each new clinic deployment feeds more longitudinal patient data,clinical records, lab results, wearable streams,back into the Florence co-pilot. This continuous data inflow improves the model's predictive accuracy for aging trajectories and intervention efficacy, which in turn improves clinical outcomes. Better outcomes drive more clinic adoption, creating a classic data network effect. The company cites its dataset as spanning 20 years for over 5 million lives, a foundation that would be prohibitively expensive and time-consuming for a new entrant to replicate [Longevity AI, 2026]. This data moat, coupled with integration stickiness within clinic workflows, can turn early pilot wins into durable account expansion.

The size of the win can be framed by looking at a comparable. Teladoc Health, a public company providing virtual care and chronic condition management, reached a market capitalization of over $20 billion at its peak. While not a perfect analog, it demonstrates the valuation potential for a software platform that becomes integral to managing population health at scale. If Longevity AI executes on the "Clalit as a launchpad" scenario and captures a material share of the global preventive and longevity-focused healthcare software market, a multi-billion dollar enterprise value is a plausible outcome (scenario, not a forecast). The company's current $5 million in disclosed funding provides a low entry point for this scale of ambition.

Partially corroborated -- Core opportunity thesis is supported by cited partnerships and product claims, but specific commercial traction metrics and detailed expansion plans are not publicly available.

Sources

Open sources

1. [Longevity AI, 2026] About Longevity AI: Mission, Team & Investors | https://www.longevity-ai.com/about

2. [Crunchbase] Longevity AI - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/longevity-ai

3. [Tracxn, 2026] Longevity AI | https://platform.tracxn.com/a/d/company/6a635d8a7142c819dfd2131a/longevity%20ai?utm_source=parallel&utm_medium=ai#a:about

4. [LinkedIn, 2026] Guy Leitersdorf - CEO Longevity AI | https://linkedin.com/in/guy-leitersdorf-21b10891

5. [LinkedIn, 2026] Kayla Raizner, MHA | https://linkedin.com/in/kayla-raizner

6. [LinkedIn, 2026] Omer Regev - Strategy & Product Manager | MBA @ LBS | https://uk.linkedin.com/in/omer-regev

7. [LinkedIn, 2026] Dani Omer | https://linkedin.com/in/dani-omer-44bb44229

8. [LinkedIn, 2026] Avia Omer | https://linkedin.com/in/avia-omer-142b84307

9. [LinkedIn, 2026] Hadar Berkman | https://linkedin.com/in/hadar-berkman

10. [LinkedIn, 2026] Aaron Schwartz - Healthcare SaaS Account Executive | https://www.linkedin.com/in/aaron-schwartz-735845240

11. [LinkedIn, 2026] Maddison Newman - 222 University of Mississippi | https://www.linkedin.com/in/maddison-newman-175041303

12. [Perplexity Sonar Pro Brief] Wellfound: Startup Jobs & AI Recruiting Platform | https://wellfound.com/

13. [21] DevJobs.co.il Job Posting | https://devjobs.co.il/job-details/4442664256

14. [Grand View Research] Longevity and Anti-Aging Market Size Report, 2030 | (URL not in provided snippets; entry omitted)

15. [Precedence Research] Digital Health Market Size Report, 2023 | (URL not in provided snippets; entry omitted)

16. [Rock Health] Digital Health Adoption Report | (URL not in provided snippets; entry omitted)